Experience

A fine
balance

The passion you want at your side, plus the experience you want at the table.

Meet Our Team

Team

Greater perspectives create greater outcomes.

Balance, diversity and passion are at the core of who we are. Meet the hardworking people who defy convention, shatter glass ceilings, and take companies to the top—all with a unique style and a healthy dose of humor.

Companies

A dynamic
portfolio.

Across healthcare and technology, we partner with companies that improve lives.

See Our Companies

Companies

The future looks bright.

Say hello to our extended family. An impressive roster of agile and imaginative companies that are building the future of healthcare and technology, one big idea at a time. Our portfolio of entrepreneurial muscle includes 59 IPOs and 134 M&As. And counting.

Approach

A hand in
every stage.

From the first handshake to the final round, we do what it takes to bring your vision to life.

Learn About Our Approach

About

This is Canaan.

Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas. While we love speedy success, we’re acutely aware that greatness comes in many forms and at different times. That’s why we’re not afraid to break the mold to bring something spectacular to life.

Experience

A fine
balance

World View

The passion you want at your side, plus the experience you want at the table.

Meet Our Team

Companies

A dynamic
portfolio.

Ideaya Biosciences

Across healthcare and technology, we partner with companies that improve lives.

See Our Companies

Approach

A hand in
every stage.

Apartment List

From the first handshake to the final round, we do what it takes to bring your vision to life.

Learn About Our Approach

Highlights

The Next Generation of Computation

Professor Robert Schoelkopf of QCI inside a lab at Yale University. Photo Credit: Roger Kisby for The New York Times

Spotlight on Wende Hutton’s 25 years in venture capital

General Partner Wende Hutton is an industry pioneer. Partner Julie Grant chatted with Wende about today’s scientific renaissance, the importance of a team approach and the difference between active and activist investor.

A Critical Marriage for Science and Health Tech

The prehistoric nature of health IT isn’t just a nuisance. It will literally determine whether patients and physicians can realize the potential of cell and gene therapies.

Video: Introducing The Makers, featuring Dan Ciporin & Amir Ashkenazi

The Makers is a new Canaan content series featuring entrepreneur and investor insights into company-building.

What Home Is

Meet our newest investment Homeis. A new kind of social network that connects foreign born locals with one another, and their roots.

What’s Rarer than a Unicorn in Silicon Valley? A Female VC.

Canaan Associate Laura Chau reflects on the 3 major takeaways she’s learned from women in venture capital.

IDEAYA & the Next Frontier in Synthetic Lethality

WSJ: Ideaya Biosciences Collects $94 Million for Cancer Therapy

The Roadmap for Board Diversity

Diversity is not window dressing. It is a positive predictor of performance and governance.

Built to Last

Excited to share news about our new $800 million fund. We know what works and we’re sticking to it with our diversified, early stage approach.

Genome Medical

Genetic sequencing technology is ahead of clinical understanding and implementation - an existential pain point for physicians.

World View

New York Times: A chicken sandwich hitches a balloon ride to the stratosphere.

The New Yorker: The RealReal’s radical vision of secondhand luxury

An inside look at how The RealReal is redefining consignment for its 8 million members (and counting).

Spotlight: Q&A with Rich Boyle

Get to know our newest GP and longtime startup operator Rich Boyle. Word to the wise: don’t throw the term AI around with him unless you mean it.

Annum

Heavy drinking is the largest ignored epidemic in the U.S. There is a superior alternative to rehab.

Body Politic Series: Women’s access to healthcare

The first installment of this series couldn’t have been more timely.

Protagonist Therapeutics

A simple promise: replacing injections with pills.

Activity

Practical tips from two male biotech CEOs who are leaning in

Video: Brendan Dickinson on how to raise money in fintech at the 2018 Empire Startups conference

Fierce Biotech: Mackay’s Rallybio rare disease startup raises $37M in first funding round

Business Insider: Adina Tecklu named under 30 rising star in Silicon Valley tech scene

Anil Singhal: My four takeaways from the AACR annual meeting

Endpoints Under 40 Feature: Julie Grant’s views on the future of biopharma

Fintech Central: Three big takeaways on how data is changing investing as we know it

FierceBiotech: GV, Roche help Ideaya to $94M crossover round, setting stage for synthetic lethality, I-O trials

STAT News: Julie Grant on how biotech’s latest bubble might go pop

The Consumerization of Enterprise & the Dropbox IPO

Fox Business: Dan Ciporin on Mornings with Maria discussing cryptocurrency

Business Insider: Wende Hutton who’s worked in venture capital for 25 years shares her best career advice — and why it was worth being the first and only woman on her team when she started out

Fortune Term Sheet: Rich Boyle – 5 Qs with a dealmaker

TechCrunch: Uncommon.co launches and raises $18m to bring objectivity and efficiency to hiring

Bloomberg Tech: Canaan Partners see race for firms to hire more women

The Marketing Power of UX Optimization

VentureBeat: ContentSquare lands $42 million so AI can track how you click, touch, and interact with brands

Women of Venture in Healthcare: 30x return on investment . . . in each other

Endpoints News: When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse?

Running a Successful SaaS Fundraising Process

TechCrunch: Apartment List raises $50 million for home rentals

CNBC: After a miserable 2017, VCs offer predictions on digital health IPOs for 2018

C&EN: Investment flows at J.P. Morgan Healthcare Conference

Endpoints News: The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

Fintech Central: Blockchain will never work in financial services & bitcoin is here to stay

FierceBiotech: Arvinas in $830M-plus Pfizer biobucks deal

SaaSQ: Building a $4B company in Silicon Valley as an outsider

You Can’t Manage What You Can’t Measure

Business Insider: AOL’s former head of video has raised money to build a Facebook-plus-Yelp-plus-Tinder for immigrants

FiercePharma: 2017’s fiercest women in life sciences

Rock Health: Meet the 2018 top 50 in digital health honorees

Boston Globe: Startup promises a weather report just for your block

Endpoints News: Six top biotech VCs take a look at the latest trends, and offer their thoughts on 2018

BioCentury Innovations: How Vivace turns the YAP pathway off or on to treat cancer

Endpoints News: Genentech inks $650M deal with protein degradation pioneer Arvinas

NY Times: Yale professors race Google and IBM to the first quantum computer

Fortune: Top women investors are answering the VC boys’ club with one of their own

VentureForward Blog: Canaan Forward – Diversity as an Asset

CNBC: 11 women who prove that health tech investing isn’t a boys’ club

FinTech Central: Bitcoin is not “closing”! And other misconceptions debunked.

Business Insider: Meet the 30 biotech leaders under 40 who are shaping the future of medicine

Elephant hunting in the HR software jungle

Recode Decode: Why one venture capitalist is ‘cringing’ at recent tech IPOs

WIRED: ExecThread opens a secret job board to the masses

USA TODAY: Peer-to-peer car rental start-up Turo heads to Germany

Brendan Dickinson: Growth Marketing: A conversation with Will Young

Entrepreneur: Why this ruthlessly prioritizing entrepreneur says you should write down one goal each day

Bloomberg: America’s drinking problem is much worse this century

Nina Kjellson: Why I’m excited to help reinvent treatment for heavy drinking

Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets

TechCrunch: Canaan Partners just closed on its biggest fund (by a lot)

WSJ: Canaan’s $800 million fund is the latest jumbo-size capital pool

Bloomberg: Canaan’s Ibrahim on VC funding environment, harassment

Fast Company: 4 life insurance startups asking millenials to face their mortality

FinTech Central: Working with the regulator

Fierce Biotech: Vivace uncloaks with $40M, U.S./China backing for cancer trials

TechCrunch: Diabetes management platform Glooko raises $35 million

Tim Shannon: Durable bonds and the birth of Vivace Therapeutics

CNBC: Startup execs urge Trump not to kill the special ‘startup visa’ for entrepreneurs

TechCrunch: In wake of Amazon/Whole Foods deal, Instacart has a challenging opportunity

LA Times: Silicon Valley’s acquisition targets aren’t in tech anymore

Variety: Tubular Labs launches branded content video tracker

Michael Beckerman: On the startup road: Canaan Partners

Steve Bloch: Breaking down barriers in genomic medicine

CNBC: A big problem with genetic testing is figuring out what the results mean. Startup Genome Medical aims to help

WSJ: Civic-based tech sees a surge

TechCrunch: What venture capitalists think of Trump

Brendan Dickinson in American Banker: As VCs pivot from lenders, case for deposit-side fintech is less clear

Brendan Dickinson: Complex logistics – a conversation with Seth Goldman, former CEO of HelloFresh USA

CNBC: Tech VCs are barging into life sciences, and writing big checks

FinTech Central: The 2nd wave of fintech

Quartz: Jeff Bezos says he’s putting billions into space. He’s not alone.

TechCrunch Equity Podcast with Maha and Hrach: Dropbox’s capital appetite and average revenue per dog

SaaSQ: How to build a billion-dollar company that delivers happiness

Rayfe Gaspar-Asaoka: How to cut through the AI hype

TechCrunch: Gaming company Kabam’s roller coaster ride to an $800M exit

STAT: Biotech dreams of drugging the “undruggable”

Colleen Cuffaro: Arrakis Therapeutics: Redefining the druggable target

BioTech Nation: Women in biotech venture capital

Joydeep Bhattacharyya: Five things every immigrant entrepreneur should do

Tim Shannon in STAT: What Trump gets wrong about drug companies

Deepak Kamra: Capella Space: Getting the full picture

TechCrunch: Zugata raises $7 million to make annual performance reviews obsolete

WSJ: Venture capital prowls into the life insurance business

Why I led Ladder’s Series A

Insurance is the next frontier for fintech

We met the dynamic duo. (And they weren’t wearing capes.)

Chats + AI: Changing the face of CRM